Eli Lilly and Company (NYSE:LLY) Position Raised by Channel Wealth LLC

05 Jun 2025, 15:14 by Jessica Moore · The Cerbat Gem

Channel Wealth LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 17.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,947 shares of the company’s stock after purchasing an additional 1,443 shares during the quarter. Eli Lilly and Company comprises 2.6% of Channel Wealth LLC’s portfolio, making the stock its 7th biggest holding. Channel Wealth LLC’s holdings in Eli Lilly and Company were worth $8,215,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of LLY. FWG Holdings LLC increased its stake in Eli Lilly and Company by 0.6% in the fourth quarter. FWG Holdings LLC now owns 2,023 shares of the company’s stock worth $1,640,000 after purchasing an additional 12 shares during the period. Morling Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 4.7% during the 4th quarter. Morling Financial Advisors LLC now owns 266 shares of the company’s stock valued at $205,000 after buying an additional 12 shares in the last quarter. Prestige Wealth Management Group LLC lifted its holdings in Eli Lilly and Company by 2.0% during the 4th quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock valued at $468,000 after buying an additional 12 shares in the last quarter. Applied Finance Capital Management LLC boosted its position in Eli Lilly and Company by 1.4% in the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock valued at $660,000 after buying an additional 12 shares during the period. Finally, Garner Asset Management Corp grew its stake in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after acquiring an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target on the stock. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Get Our Latest Stock Analysis on Eli Lilly and Company

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 2.1%

Shares of NYSE:LLY opened at $766.78 on Thursday. The business’s 50-day moving average is $772.75 and its 200 day moving average is $799.41. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm has a market capitalization of $726.71 billion, a P/E ratio of 65.48, a P/E/G ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same period in the previous year, the business earned $2.58 earnings per share. The business’s revenue for the quarter was up 45.2% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Eli Lilly and Company Profile

(Free Report)